Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1LG2 | Q9BQ51 | 4/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22885900 | 0.77 | PDCD1LG2 (0.37) | PDCD1LG2CD274MEN1CYP1A2CYP3A4 | |
| SCHEMBL7665261 | 0.71 | SLC6A4 (0.39) | CD274 | |
| SCHEMBL3754378 | 0.70 | CD274 (0.43) | PDCD1LG2CD274MEN1KMT2A | |
| SCHEMBL3722644 | 0.68 | TRPV3 (0.40) | PDCD1LG2CD274 | |
| SCHEMBL4537748 | 0.66 | PDCD1LG2 (0.34) | PDCD1LG2CD274 | |
| SCHEMBL3719502 | 0.66 | MAPT (0.36) | PDCD1LG2CD274MEN1KMT2A | |
| SCHEMBL3722429 | 0.66 | MAPT (0.36) | PDCD1LG2CD274MEN1KMT2A | |
| SCHEMBL3719739 | 0.66 | MAPT (0.36) | PDCD1LG2CD274MEN1KMT2A | |
| SCHEMBL4570112 | 0.65 | NPC1 (0.33) | PDCD1LG2CD274MEN1KMT2A | |
| SCHEMBL3741159 | 0.65 | PDCD1LG2 (0.38) | PDCD1LG2CD274MEN1CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010132015-A1 | NEW COMPOUNDS MODULATING GAMMA-SECRETASE AND THEIR USE IN THE TREATMENT OF ALPHA BETA RELATED PATHOLOGIES, SUCH AS ALZHEIMER'S DISEASE | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | disclosed |